Shaily Engineering Plastics Limited, a leading developer and manufacturer of drug delivery systems, announced that its strategic partner Orbicular Pharmaceutical Technologies in partnership with its customer has launched a generic version of Semaglutide injection in Canada, incorporating Shaily’s proprietary spring-driven ShailyPen Neo pen platform. 

 

ShailyPen Neo is among a rare class of commercially available spring-driven pen injectors globally. It is a high-performance, variable and fixed-dose platform offering full compatibility with ISO-standard 3 mL cartridges (3 mL and 1.5 mL fill). 

Shaily’s role in this program relates to full design and development, and manufacturing and supply of the device components used in the approved combination product.

Amit Sanghvi, Managing Director, Shaily Engineering Plastics Limited said, “This achievement is one we carry with a great deal of humility. ShailyPen Neo did not happen by accident. Spring-driven pen injector technology sits within a highly restricted IP environment, and bringing a platform of this caliber to regulatory approval was never going to be easy. We recognized early that spring-actuated pen injectors would become a critical enabler in injectable therapies, and we made a genuinely bold bet."